Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
about
Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetesNitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunctionUpdate on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseTreatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortasDiabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature.Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.Angiotensin II modulates interleukin-1β-induced inflammatory gene expression in vascular smooth muscle cells via interfering with ERK-NF-κB crosstalkRole of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis.An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunctionDeletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice.Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.How to best manage glycemia and non-glycemia during the time of acute myocardial infarction.Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetesCognition and Hemodynamics.Pharmacological basis of different targets for the treatment of atherosclerosis.The Establishment and Characteristics of Rat Model of Atherosclerosis Induced by HyperuricemiaPPAR Agonists and Cardiovascular Disease in Diabetes.Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice.The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases.Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice.Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction.Endothelial effects of antihypertensive treatment: focus on irbesartanReceptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.Vascular benefits of angiotensin receptor blockers.AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγAmlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits.The AGE/RAGE axis in diabetes-accelerated atherosclerosis.Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic miceAngiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study.Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis.Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions.Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers.Novel pathways and therapies in experimental diabetic atherosclerosis.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
P2860
Q24608214-9397583A-C940-479F-AFEC-051A88F40D5EQ26830607-ADCD742C-5607-4308-878F-6EB74864EBC5Q28077454-FB100046-B172-4AB0-A1D5-41026B24490CQ28577025-ECDE3865-A056-4527-8947-6B9B3EEF9F4EQ34350546-7891C4E4-2A74-46C0-A622-87E545CE003AQ34355358-419895F8-8566-48FA-8A26-FC3C0543939DQ34550600-DC7E80B8-0A41-4472-9C9B-C54BE3876037Q35116630-78A63EBC-2CE3-4F47-AB44-2A5666AFD855Q35141843-B0EA04D8-2A2F-4E7F-92EC-9CABB7520E5BQ35569854-187D671F-74DE-4009-BF25-CCF13845F821Q35923732-CC4EF1D6-A23F-4081-B8A9-9500C94C2106Q36012843-CEEA378F-73FB-435E-A530-D2A2DF91D6E5Q36018270-D194F7AC-BE29-4821-94CB-2019DCE2DA56Q36025434-77A91705-60BB-4044-AFB6-67B539746663Q36072601-CFD1FB08-2642-4AC0-9F42-0CC9D059BEF4Q36222092-0FBF4289-FAFD-440D-B9F6-C3C5FF7E17CCQ36292056-D7864BD1-B2FB-4BD1-B6C5-79B92B609693Q36346487-BF048D78-3072-44DD-B44D-E9BB42566F26Q36405350-9977949F-6CDF-4915-A655-428E6311AB6EQ36444975-C691E8A1-0C61-45EC-ABB1-DCD2375B048AQ36458652-8E831B5C-48E1-4593-B394-E50079AE3E41Q36532932-9A4B7910-A5C6-491A-830A-6E4CFC89FB00Q36599243-2964724A-B3E4-43AA-8A03-52526B3C1C6CQ36688756-AF21376F-1C80-47EF-A6BE-9406CBD0A29AQ36744061-67AC7E8E-1680-4B36-A294-06DE15DF812DQ36766914-78217140-9CD2-47C3-B225-9B6E14FD3E9EQ36842628-3BB49350-8004-4F87-93F6-3C44F147323CQ36861584-0C8D3731-4D7B-450B-87D6-DE6AD2CFE866Q36885183-C595D755-CB59-4691-8E5C-D908EA1C58C6Q37041493-56D1E107-6E4F-470A-ACBA-E3A36539CEEAQ37091107-338694E4-B79E-4754-99D4-BD4BD7F7AFF8Q37163462-407C4E00-93EE-4259-B192-A3698395A7D4Q37308953-4BF3A8A8-8793-495F-A272-91DCF88B5CE9Q37391675-DC332A23-498A-40A7-AADC-1FBC9F386170Q37404651-DAF55386-3CE1-4BE4-8D08-C0F37ECAB3D2Q37486465-7A5E9055-D779-4711-8A3D-F987C88207A8Q37518158-F370C729-E0C4-48E2-9B85-A93B909A4105Q37990618-12BEAC12-41AF-403E-A8E7-FA0C3BE79A9DQ38200957-4985AC02-EAF9-41C8-A3FE-342B229A31E2Q38771740-6F4E1CFE-A3A7-4591-89DE-5F0A77137210
P2860
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@en
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@nl
type
label
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@en
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@nl
prefLabel
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@en
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@nl
P2093
P1433
P1476
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
@en
P2093
Karin A Jandeleit-Dahm
Mark E Cooper
Markus Lassila
Riccardo Candido
Terri J Allen
Vicki Thallas
P304
P356
10.1161/01.CIR.0000124061.78478.94
P407
P577
2004-03-15T00:00:00Z